• Saved

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Source : https://doi.org/10.1080/14712598.2021.1872540

ABSTRACT Introduction: B-cell maturation antigen (BCMA) targeted therapy (BCMA-TT) has emerged as a promising treatment for Multiple Myeloma (MM). the three most common treatment modalities for targeting BCMA are antibody-drug conjugates (ADCs), bispecific antibody constructs, including BiTE (bispecific T-cell engager) immuno-oncology therapies, and chimeric antigen receptor (CAR)-modified T-cell therapy.